CytomX, AbbVie deal

CytomX and AbbVie partnered to co-develop and co-commercialize Probody drug conjugates against transferrin receptor ( TFRC; TFR). CytomX’s Probody technology uses tumor microenvironment to enhance antibody targeting. CytomX will be responsible for development through the completion of Phase I testing, and AbbVie will be responsible for later development and commercialization. The partners will share late-stage development costs. ...